@CDiddyQuote:Clearly. Blafarm, seems like you are trying awefully hard this time to find things to nitpick. Guess that means Nader is improving.
Is it really too much to ask for a clearly worded PR that doesn't take the members of this board days to unpack? Because that's what we've been doing for months now -- trying to decipher the meaning and ramifications of poorly drafted PRs. I will resist the temptation to discuss conference call issues, as it is an entirely unproductive line of thought.
I am not a mindless cheerleader, and I don't subscribe to the flavor of blind optimism that had some members here fanatically believing that today's outcome was going to include all manner of approvals.
I say, live and let live. However, I am weary of my objective and analytical nature being misconstrued and distorted to imply that I am a short and a basher. There is no short or basher in the world that has spent this much time and invested this much money in a stock they were trying to hammer.
Lastly, I will say that I firmly believe today's outcome was excellent. We are in the pipe, five by five. The 293 interim is designed to succeed and it has largely de-risked this investment and CytoDyn's ability to fund future indications.
I can't wait for the readout.